ES2152496T3 - Compuestos pentaciclicos, intermediarios, procesos, composiciones y procedimientos. - Google Patents

Compuestos pentaciclicos, intermediarios, procesos, composiciones y procedimientos.

Info

Publication number
ES2152496T3
ES2152496T3 ES96306351T ES96306351T ES2152496T3 ES 2152496 T3 ES2152496 T3 ES 2152496T3 ES 96306351 T ES96306351 T ES 96306351T ES 96306351 T ES96306351 T ES 96306351T ES 2152496 T3 ES2152496 T3 ES 2152496T3
Authority
ES
Spain
Prior art keywords
sub
sup
compounds
rent
procedures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96306351T
Other languages
English (en)
Inventor
Timothy Alan Grese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2152496T3 publication Critical patent/ES2152496T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Mechanical Pencils And Projecting And Retracting Systems Therefor, And Multi-System Writing Instruments (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE FORMULAS I Y II; DONDE X ES -O-, -S-, O -NR{SUP,5}-; Y ES -O-, -S-, -CH{SUB,2}-, -CH{SUB,2}CH{SUB,2}-, -CH=CH-, O -NR{SUP,5}-; B ES -CH{SUB,2}- O -CO-; R{SUP,1}, R{SUP,2} Y R{SUP,3} SON CADA UNO INDEPENDIENTEMENTE -H, -OH, -O(ALQUILO C{SUB,1}-C{SUB,4}), -OCO(ALQUILO C{SUB,1}C{SUB,6}), -OSO{SUB,2}(ALQUILO C{SUB,4}-C{SUB,6}, OSO{SUB,2}CF{SUB,3}, CL O F; N ES 1 O 2; W ES CH{SUB,2} O C=O; R{SUP,4} ES 1-PIPERIDINIL, 2-OXO-1-PIPERIDINIL, 1-PIRROLIDINIL, METIL-1-PIRROLIDINIL, DIMETIL-1-PIRROLIDINIL, 2-OXO-1PIRROLIDINIL, 4-MORFOLINO, DIMETILAMINO, DIETILAMINO, O 1HEXAMETILENOIMINO; R{SUP,5} ES ALQUILO C{SUB,1}-C{SUB,3}, -COC{SUB,6}H{SUB,5}, CO(ALQUILO C{SUB,1}-C{SUB,6}), -C(O)OC{SUB,6}H{SUB,5}, -C(O)O(ALQUILO C{SUB,1}-C{SUB,6}), -SO{SUB,2}C{SUB,6}H{SUB,5}, O -SO{SUB,2}CF{SUB,3}, O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO. TAMBIEN SE PROPORCIONAN EN LA PRESENTE INVENCION COMPUESTOS INTERMEDIOS; PROCEDIMIENTOS DE PREPARACION DE LOS COMPUESTOS DE FORMULAS I Y II; Y METODOS FARMACEUTICOS Y FORMULACIONES QUE EMPLEAN DICHOS COMPUESTOS.
ES96306351T 1995-09-08 1996-09-02 Compuestos pentaciclicos, intermediarios, procesos, composiciones y procedimientos. Expired - Lifetime ES2152496T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US349695P 1995-09-08 1995-09-08

Publications (1)

Publication Number Publication Date
ES2152496T3 true ES2152496T3 (es) 2001-02-01

Family

ID=21706148

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96306351T Expired - Lifetime ES2152496T3 (es) 1995-09-08 1996-09-02 Compuestos pentaciclicos, intermediarios, procesos, composiciones y procedimientos.

Country Status (25)

Country Link
US (3) US5726186A (es)
EP (1) EP0761669B1 (es)
JP (1) JP3688299B2 (es)
KR (1) KR19990044422A (es)
CN (1) CN1201392A (es)
AT (1) ATE197712T1 (es)
AU (1) AU705454B2 (es)
BR (1) BR9610356A (es)
CA (1) CA2230974A1 (es)
CZ (1) CZ286236B6 (es)
DE (1) DE69611015T2 (es)
DK (1) DK0761669T3 (es)
EA (1) EA001649B1 (es)
ES (1) ES2152496T3 (es)
GR (1) GR3035253T3 (es)
HU (1) HUP9802213A3 (es)
IL (1) IL123560A (es)
MX (1) MX9801734A (es)
NO (1) NO980936L (es)
NZ (1) NZ318183A (es)
PL (1) PL325479A1 (es)
PT (1) PT761669E (es)
SI (1) SI0761669T1 (es)
TR (1) TR199800387T1 (es)
WO (1) WO1997009044A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
JPH11510479A (ja) 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
WO2000037083A1 (en) * 1998-12-18 2000-06-29 Schering Corporation Oral antiestrogen pharmaceutical composition
US7105679B2 (en) 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
US7329654B2 (en) * 2001-12-19 2008-02-12 Janssen Pharmaceutica N.V. Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
WO2004009578A2 (en) * 2002-07-24 2004-01-29 Eli Lilly And Company Pentacyclic oxepines and derivatives thereof, process for their preparation and pharmaceutical compositions containing them
WO2004009603A1 (en) * 2002-07-24 2004-01-29 Eli Lilly And Company Dihydro-dibenzo[b,e]oxepine based selective estrogen receptor modulators, compositions and methods
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法
BR0314594A (pt) * 2002-09-25 2005-08-09 Lilly Co Eli Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, método para inibir uma doença associada com deprivação de estrogênio, método para inibir uma doença associada com uma resposta fisiológica aberrante a estrogênio endógeno, e, uso de um composto
US6894061B2 (en) 2002-12-04 2005-05-17 Wyeth Substituted dihydrophenanthridinesulfonamides
US7074779B2 (en) * 2003-07-02 2006-07-11 Ortho-Mcneil Pharmaceutical, Inc. Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors
UA85862C2 (uk) 2004-01-22 2009-03-10 Елі Ліллі Енд Компані Селективні модулятори рецепторів естрогену для лікування вазомоторних симптомів
CN1910167B (zh) * 2004-01-22 2011-08-10 伊莱利利公司 用于治疗血管舒缩症状的选择性雌激素受体调节剂
WO2005073244A1 (en) * 2004-01-22 2005-08-11 Eli Lilly And Company Selective estrogen receptor modulators
KR20150039882A (ko) 2010-06-16 2015-04-13 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
WO2013064206A1 (de) * 2011-11-01 2013-05-10 Merck Patent Gmbh Organische elektrolumineszenzvorrichtung
US8829993B2 (en) 2012-10-30 2014-09-09 Eta Devices, Inc. Linearization circuits and methods for multilevel power amplifier systems
CN109678878A (zh) * 2019-02-27 2019-04-26 陕西科技大学 一种苯并噻吩并香豆素类化合物及其合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2884427A (en) * 1958-01-22 1959-04-28 Oliver H Emerson Synthesis of coumestrol and its esters
US2987398A (en) * 1958-05-12 1961-06-06 Emanuel M Bickoff Coumestrol ethers and use thereof
US3912740A (en) * 1974-02-28 1975-10-14 Us Health Method for the preparation of oxygenated benzo{8 c{9 phenanthridine compounds
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4659671A (en) * 1983-07-01 1987-04-21 Massachusetts Institute Of Technology Enzymatic separation of racemic mixtures of hydroxy compounds
CA2054569A1 (en) * 1990-11-07 1992-05-08 Masanobu Suzuki Process for preparing benzo¬c|phenanthridinium derivatives, and novel compounds prepared by said process
US5147880A (en) * 1991-07-22 1992-09-15 Eli Lilly And Company Benzo[a]fluorene compounds
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5336687A (en) * 1993-08-04 1994-08-09 American Home Products Corporation Inhibition of bone loss by 4-aryloxy-5-hydroxy-2(5H)-furanones

Also Published As

Publication number Publication date
KR19990044422A (ko) 1999-06-25
DE69611015D1 (de) 2000-12-28
NZ318183A (en) 1998-09-24
US6004971A (en) 1999-12-21
SI0761669T1 (en) 2001-04-30
NO980936D0 (no) 1998-03-04
BR9610356A (pt) 1999-07-06
IL123560A (en) 2002-02-10
DE69611015T2 (de) 2001-05-10
ATE197712T1 (de) 2000-12-15
GR3035253T3 (en) 2001-04-30
US5726186A (en) 1998-03-10
AU705454B2 (en) 1999-05-20
CZ67898A3 (cs) 1998-06-17
JP3688299B2 (ja) 2005-08-24
TR199800387T1 (xx) 1998-05-21
NO980936L (no) 1998-05-07
PT761669E (pt) 2001-04-30
EA001649B1 (ru) 2001-06-25
US6133288A (en) 2000-10-17
CN1201392A (zh) 1998-12-09
EP0761669A2 (en) 1997-03-12
EP0761669A3 (en) 1997-10-29
CA2230974A1 (en) 1997-03-13
PL325479A1 (en) 1998-07-20
JPH11514347A (ja) 1999-12-07
EA199800278A1 (ru) 1998-08-27
EP0761669B1 (en) 2000-11-22
IL123560A0 (en) 1998-10-30
HUP9802213A2 (hu) 1999-02-01
WO1997009044A1 (en) 1997-03-13
AU6959096A (en) 1997-03-27
CZ286236B6 (cs) 2000-02-16
HUP9802213A3 (en) 2000-03-28
MX9801734A (es) 1998-08-30
DK0761669T3 (da) 2000-12-11

Similar Documents

Publication Publication Date Title
ES2152496T3 (es) Compuestos pentaciclicos, intermediarios, procesos, composiciones y procedimientos.
FI963424A0 (fi) Menetelmä terapeuttisesti aktiivisten tiofeenisulfonamidien valmistamiseksi
LU88306I2 (fr) Felodipine (Plendil)
DK0395329T4 (da) Sammensætning i form af et skum indeholdende 5-aminosalicylsyre til intrarektal administration
IL69175A (en) 3,5-dimethyl-4-methoxy pyridyl-n-oxides,their preparation and their use as intermediates for the preparation of omeprazole derivatives
DE3365772D1 (en) 1,4-dihydropyridines, process for their preparation and their application as pharmaceutical preparations
NO863823L (no) 1,5-benzothiazepinderivater som er anvendelige som utgangsmaterialer ved fremstilling av nye, terapeutisk aktive 8-klor-1,5-benzothiazepinderivater, og fremgangsmaate ved deres fremstilling.
DK132789A (da) 9-halogen-(z)-prostaglandinderivater, fremgangsmaade til deres fremstilling og deres anvendelse som laegemiddel
ES520803A0 (es) Un procedimiento para fabricar pastillas de jabon molido.
DK0550612T3 (da) Ny fremgangsmåde til fremstilling af formoterol ogbeslægtede forbindelser
FI792939A (fi) Fluorhaltiga 1,4-dihydropyridiner foerfarande foer framstaellning av dem och deras anvaendning som laekemedel
CO4480019A1 (es) Liposomas de cetoprofeno
DK359387D0 (da) Oploesninger af oxazaphosphoriner med forbedret stabilitet og fremgangsmaade til deres fremstilling
OA09454A (fr) Nouveaux dérivés peptidiques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
NO854565L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 6- eller 9-klor-1,5-benzothiazepinderivater.
DE3364462D1 (en) Process for the preparation of acemetacin
DE59104469D1 (de) Dialkoxybenzylidenkampfer-Derivate.
FR2623504B1 (fr) Nouveaux derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
ES2053755T3 (es) Un procedimiento para preparar compuestos heterociclicos.
SE8306225L (sv) 2-piperazinyl-kinazolinderivat, deras framstellning och farmaceutiska kompositioner innehallande desamma
DK12584A (da) Bicyclo(4.2.0)1,3,5-octatrienderivater, fremgangsmaade til deres fremstilling og farmaceutiske kompositioner indeholdende disse
DE3273389D1 (en) Derivatives of pentacyclo undecanes, processes for preparing these compounds, and pharmeceutical compositions thereof
YU45932B (sh) Postupak za dobijanje 2-benzimidazolilalkiltio ili sulfinil ili sulfonil derivata
DK303081A (da) Fremgangsmaade til fremstilling af propanolaminderivater eller slte deraf
ES2038612T3 (es) Compuestos de hidroquinolina, composiciones que los contienen y procedimientos para prepararlas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 761669

Country of ref document: ES